These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Chiou SH; Dorsch M; Kusch E; Naranjo S; Kozak MM; Koong AC; Winslow MM; Grüner BM Sci Rep; 2018 Sep; 8(1):14008. PubMed ID: 30228296 [TBL] [Abstract][Full Text] [Related]
10. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas. Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504 [TBL] [Abstract][Full Text] [Related]
11. High-mobility group A2 overexpression is an unfavorable prognostic biomarker for nasopharyngeal carcinoma patients. Liu Z; Wu K; Yang Z; Wu A Mol Cell Biochem; 2015 Nov; 409(1-2):155-62. PubMed ID: 26183485 [TBL] [Abstract][Full Text] [Related]
12. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Li K; Yang J; Chen J; Shi Y; Zhang Z; Chen W Oncol Lett; 2020 Feb; 19(2):1584-1592. PubMed ID: 31966084 [TBL] [Abstract][Full Text] [Related]
13. Glypican-3 and KRT19 are markers associating with metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Yao H; Yang Z; Liu Z; Miao X; Yang L; Li D; Zou Q; Yuan Y Cancer Biomark; 2016; 17(4):397-404. PubMed ID: 27689616 [TBL] [Abstract][Full Text] [Related]
14. MiR-590 Suppresses Proliferation and Induces Apoptosis in Pancreatic Cancer by Targeting High Mobility Group A2. Wang YD; Mao JD; Wang JF; Xu MQ Technol Cancer Res Treat; 2020; 19():1533033820928143. PubMed ID: 32588766 [TBL] [Abstract][Full Text] [Related]
15. A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer. Paladino D; Yue P; Furuya H; Acoba J; Rosser CJ; Turkson J Oncotarget; 2016 Feb; 7(6):7253-67. PubMed ID: 26695438 [TBL] [Abstract][Full Text] [Related]
16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360 [TBL] [Abstract][Full Text] [Related]
17. Association of subcellular localization of TEAD transcription factors with outcome and progression in pancreatic ductal adenocarcinoma. Drexler R; Fahy R; Küchler M; Wagner KC; Reese T; Ehmke M; Feyerabend B; Kleine M; Oldhafer KJ Pancreatology; 2021 Jan; 21(1):170-179. PubMed ID: 33317954 [TBL] [Abstract][Full Text] [Related]
18. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer. Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873 [TBL] [Abstract][Full Text] [Related]
19. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas. Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611 [TBL] [Abstract][Full Text] [Related]
20. Lack of CCR7 expression is rate limiting for lymphatic spread of pancreatic ductal adenocarcinoma. Sperveslage J; Frank S; Heneweer C; Egberts J; Schniewind B; Buchholz M; Bergmann F; Giese N; Munding J; Hahn SA; Kalthoff H; Klöppel G; Sipos B Int J Cancer; 2012 Aug; 131(4):E371-81. PubMed ID: 22020953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]